What is it about?

This manuscript describes the design of a clinical trial (JAVELIN Ovarian 200) investigating whether treatment with avelumab, an immunotherapy, can improve clinical outcomes for patients with ovarian cancer who have had a disease relapse after receiving chemotherapy.

Featured Image

Read the Original

This page is a summary of: Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design, Future Oncology, March 2018, Taylor & Francis,
DOI: 10.2217/fon-2018-0070.
You can read the full text:

Read

Contributors

Be the first to contribute to this page